All Stories

  1. Approval lag and loss for biologic-device combination products in Japan and the United States
  2. Important potential risks not reflected in Japanese drug labeling: implications for risk management plan termination
  3. Race and trial region changes in cancer clinical trials between 2013 and 2024
  4. Important missing information in Japan's risk management plans: a cross-sectional analysis after a decade of implementation
  5. Post‐Marketing Requirements for Anticancer Drugs Approved in Japan, 2001–2024: A Cross‐Sectional Analysis
  6. Identifying Factors Associated with the Acquisition of Multiple Indications for Anticancer Drugs
  7. Dose optimization in FDA oncology drug approvals: Factors associated with observing exposure-efficacy relationships.
  8. Tumor‐Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development
  9. Adverse Event Reports and Safety Measures for Breast Implant–associated Anaplastic Large Cell Lymphoma in Japan
  10. Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysis
  11. A landscape analysis of Japanese tolerability assessments in oncology drug development
  12. Interactions Between Pharmaceutical Companies and Patient Advocacy Groups in Japan: A Qualitative and Quantitative Interview Study
  13. Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States
  14. A cross-sectional study on the first-in-human trials of anticancer drugs in Japan and the United States and the probability of approval
  15. Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs
  16. Consideration on Food Effect Studies for Anticancer Drugs Approved in Japan Between 2001 and 2022
  17. Characterization of Japanese Risk Management Plans after 10 Years of Implementation: 2013–2023
  18. Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis
  19. Added Therapeutic Benefits of Top‐Selling Drugs in Japan: A Cross‐Sectional Study Using Health Technology Assessment
  20. Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments
  21. Cross-sectional Study and Comparison between Japan and the United States on Special Regulatory Pathways for Expedited Drug Development and Approval
  22. Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis
  23. Cross-sectional Study on Sex Disparities among Japanese and Korean University School of Pharmacy Professors
  24. Gender differences in pharmacy professors in Japan and Korea
  25. Comparison of National Lists of Essential Medicine among Japan, the United States of America, the European Union, the World Health Organization, Thailand, and China
  26. Has risk management plan system influenced the speed of package insert revisions in Japan?
  27. Comparison of regulatory approval system for medicines in emergency among Japan, the United States, the United Kingdom, Europe, and China
  28. Trends in the market for drug delivery devices categorized as combination drugs and medical devices and regulatory challenges for autoinjectors in Japan
  29. A Qualitative Interview Study on Expanded Access Clinical Trials for Compassionate Use in Japan
  30. Current situation and issues regarding termination of risk management plans in Japan
  31. Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review
  32. Trends in oncology drug lags in Japan from 2001–2020
  33. Patient enrollment speed for clinical trials in Japan
  34. Comparing cancer drug approval systems in the United States and Japan
  35. Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan
  36. Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
  37. Postmarketing all-case surveillance trends and contribution to safety measures of drugs approved in Japan: a cross-sectional survey in 1999–2019
  38. O16-6 Consideration for the trends on drug lag in oncology drugs during the last two decades in Japan; 2001-2020
  39. Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021
  40. Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan
  41. Lag Time for New Innovative, First-in-Class, Drug Approval in Japan
  42. The Current Status and Future Direction of Clinical Research in Japan From a Regulatory Perspective
  43. Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan
  44. Study of the compatibility of oral magnesium oxide preparations sold in Japan with the ICH-Q3D guideline for elemental impurities
  45. Relationships between Developmental Strategies for Additional Indications and Price Revisions for Anticancer Drugs in Japan
  46. Medical Affairs in Pharmaceutical Companies and Related Pharmaceutical Regulations in Japan
  47. Assessment of Drugs Approved by Public Knowledge‐Based Applications ( Kouchi‐shinsei ) During the Last Two Decades in Japan
  48. Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic
  49. Surrogate endpoint for prostate cancer
  50. 医薬品開発におけるリアルワールドデータの利活用(Regulatory approval with real world data from regulatory science perspective)
  51. プログラム
  52. 演者紹介
  53. Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study
  54. A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
  55. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
  56. Reply to the letter to the editor ‘Surrogate end points for overall survival.Festina lente (more haste, less speed)’ by Braillon
  57. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States
  58. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency
  59. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries
  60. Involvement of Anticancer Drugs in the Relief System for Adverse Drug Reactions in Japan
  61. The Efficacy and Safety of Degarelix, a GnRH Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phase II Study in Japanese Patients with Prostate Cancer
  62. The efficacy and safety of degarelix, a GnRH receptor antagonist: A multicenter, randomized, maintenance dose-finding phase II study with Japanese prostate cancer patients.
  63. Modulation of Glutathione S-Transferase Activity by a Thiol/Disulfide Exchange Reaction and Involvement of Thioltransferase
  64. Study on Human Erythrocyte Thioltransferase: Comparative Characterization with Bovine Enzyme and Its Physiological Role under Oxidative Stress
  65. Inactivation of human placenta glutathione S-transferase by SHSS exchange reaction with biological disulfides